Drug reference

duvelisib

PI3Kδ and PI3Kγ inhibitor · Antineoplastic agent

PI3Kδ and PI3Kγ inhibitorAntineoplastic agent

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

12 major

SEVERE in our sources

PREGNANCY

FDA category + note

Top interactionssee all 12 →

AcalabrutinibSevereDatabaseDDInter
AdalimumabSevereDatabaseDDInter
AlfentanilSevereDatabaseDDInter
ApalutamideSevereDatabaseDDInter

Mechanism

Duvelisib is an orally bioavailable inhibitor of PI3Kδ and PI3Kγ. The potency of duvelisib against the β and α isoforms is lower.

Indications

relapsed or refractory CLL, SLL, or FL after at least two prior therapies

Pharmacokinetics

Half-life

4.7 h (elimination)

Metabolism

CYP3A4

Side effects

Serious

infections (31% of patients)
diarrhea and colitis (18%)
pneumonitis (5%)

Pregnancy & lactation

Pregnancy

Drug interactions

Acalabrutinib

Severe

Database

Drug interaction classified as: metabolism

Source: DDInter

Adalimumab

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Alfentanil

Severe

Database

Drug interaction classified as: metabolism

Source: DDInter

Apalutamide

Severe

Database

Drug interaction classified as: metabolism

Source: DDInter

Atazanavir

Severe

Database

Drug interaction classified as: metabolism

Source: DDInter

Avanafil

Severe

Database

Drug interaction classified as: metabolism

Source: DDInter

Avapritinib

Severe

Database

Drug interaction classified as: metabolism

Source: DDInter

Baricitinib

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Benzhydrocodone

Severe

Database

Drug interaction classified as: metabolism

Source: DDInter

Boceprevir

Severe

Database

Drug interaction classified as: metabolism

Source: DDInter

Bosutinib

Severe

Database

Drug interaction classified as: metabolism

Source: DDInter

Brexpiprazole

Severe

Database

Drug interaction classified as: metabolism

Source: DDInter

Related guidelines

Heart failure in diabetes

RSSDI · Cardiology · 2023

Hypertension in adults

ICMR · Cardiology · 2019

Generalised anxiety disorder and panic disorder

NICE · Psychiatry · 2020

Hypertrophic cardiomyopathy

ESC · Cardiology · 2026

Diabetes management in chronic kidney disease

KDIGO · Nephrology · 2022

Ask House about duvelisib

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspace Ask House about this drug

Textbook-sourced·Sources: Goodman & Gilman 14e·Updated: 2026-05-10